<DOC>
	<DOC>NCT02687139</DOC>
	<brief_summary>In this study the investigators aim to evaluate diagnostic utility of PSMA-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma.</brief_summary>
	<brief_title>Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>Clinically diagnosed or histologically proven stage IIIV renal cell carcinoma Completed staging evaluation with computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis â‰¤90 days prior to study enrollment History of other malignancy diagnosed within the last 3 years (with the exception of low risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell carcinoma or basal cell carcinoma of the skin) Administered a radioisotope within 5 physical halflives prior to study enrollment Pregnancy ((as determined in accordance with the policies of the positron emission tomography (PET) center)) Intention to enroll in a blinded therapeutic clinical trial following Positron emission tomographycomputed tomography (PET/CT)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>